Hol Janna A, van den Heuvel-Eibrink Marry M, Graf Norbert, Pritchard-Jones Kathy, Brok Jesper, van Tinteren Harm, Howell Lisa, Verschuur Arnauld, Bergeron Christophe, Kager Leo, Catania Serena, Spreafico Filippo, Mavinkurve-Groothuis Annelies M C
Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Department of Pediatric Oncology & Hematology, Saarland University, Homburg, Germany.
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26849. Epub 2017 Oct 27.
While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.
虽然伊立替康已在多种小儿实体瘤中进行了研究，但其在肾母细胞瘤（WT）中的潜在作用尚不清楚。我们评估了含伊立替康方案在复发WT中的反应和结局，并将我们的结果与现有文献进行了比较。在14例可评估患者中，初始为中危（完全缓解和部分缓解）且组织学类型为胚芽型（部分缓解）的患者中观察到1例完全缓解（CR）和2例部分缓解（PR）。最后一次随访时有2例患者存活，无疾病证据。我们的结果及综述文献表明伊立替康在复发WT的治疗中具有一定疗效。
